Abstract:Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group, these reports suggest that patients should continue to be immunized with additional doses to attempt to improve immune response but that they need to maintain the precautions recommended for the unvaccinated.
“…Of note, 4 of the 5 patients who failed to seroconvert after the two first doses of the vaccine responded to the booster dose. These data are in line with prior reports assessing binding Ab responses to a third dose of mRNA vaccine in allo-HCT patients ( Redjoul et al., 2021a ; Maillard et al., 2022 ).…”
Section: Main Textsupporting
confidence: 92%
“…Allogeneic hematopoietic stem cell transplant (allo-HCT) recipients are particularly at risk of severe COVID-19. In addition, they have lower serological response to two doses of mRNA vaccines as compared to healthy individuals ( Redjoul et al., 2021a ; Canti et al., 2021 ; Maillard et al., 2022 ). Whether they are protected following vaccination against the Delta and Omicron variants remains to be established.…”
Section: Main Textmentioning
confidence: 99%
“…Three prior studies have assessed the impact of a third dose vaccine in allo-HCT recipients ( Redjoul et al., 2021b ; Le Bourgeois et al., 2021 ; Maillard et al., 2022 ). Redjoul et al.…”
Section: Main Textmentioning
confidence: 99%
“…More recently, Maillard et al. investigated the impact of a third dose vaccine in 181 allo-HCT recipients ( Maillard et al., 2022 ). The third vaccine was given a median of 54 days after dose 2.…”
“…Of note, 4 of the 5 patients who failed to seroconvert after the two first doses of the vaccine responded to the booster dose. These data are in line with prior reports assessing binding Ab responses to a third dose of mRNA vaccine in allo-HCT patients ( Redjoul et al., 2021a ; Maillard et al., 2022 ).…”
Section: Main Textsupporting
confidence: 92%
“…Allogeneic hematopoietic stem cell transplant (allo-HCT) recipients are particularly at risk of severe COVID-19. In addition, they have lower serological response to two doses of mRNA vaccines as compared to healthy individuals ( Redjoul et al., 2021a ; Canti et al., 2021 ; Maillard et al., 2022 ). Whether they are protected following vaccination against the Delta and Omicron variants remains to be established.…”
Section: Main Textmentioning
confidence: 99%
“…Three prior studies have assessed the impact of a third dose vaccine in allo-HCT recipients ( Redjoul et al., 2021b ; Le Bourgeois et al., 2021 ; Maillard et al., 2022 ). Redjoul et al.…”
Section: Main Textmentioning
confidence: 99%
“…More recently, Maillard et al. investigated the impact of a third dose vaccine in 181 allo-HCT recipients ( Maillard et al., 2022 ). The third vaccine was given a median of 54 days after dose 2.…”
“…(2021) showed that a third dose of BNT162b2 mRNA vaccine led to a significant increase in anti-SARS-CoV-2 IgG antibodies (from 737 AU/mL to 11,099 AU/mL; p = 0.00069) in 42 alloHCT recipients. Maillard et al. (2022) showed that 41% of patients (29/70) developed a detectable response after the third dose after not responding to the first two doses.…”
This cohort study assesses the incidence and severity of COVID-19 among vaccinated recipients of allogenic stem cell transplant in a single center after 1 or 2 messenger RNA booster doses during the Omicron wave in France.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.